Stock Market & Financial Investment News

Synageva should be bought at current levels, says RW BairdBaird said their investment thesis for Synageva remains unchanged following its successful display at the WORLD symposium last month. The firm recommends purchase at current levels as the company heads into an important value-creating period which includes potential pivotal data for a lead compound and the beginning of clinical trials for SBC-103. Shares are Outperform rated with a $107 price target.